In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 70, No. 8_Supplement ( 2010-04-15), p. 3292-3292
Kurzfassung:
Background: The assessment of tumor receptor profile (ER, PR, and HER-2) is necessary to select patients who are candidate for hormonal and anti-HER-2 therapy. The occurrence of changes in tumor receptor profile (ER, PR and HER-2) between primary and metachronous metastatic tissue has been recognized, which might have significant implications in terms of treatment. The primary aim of this analysis was to compare ER, PR and HER-2 status in primary tumor versus metastatic sites in breast cancer patients. Materials and Methods: Thirty patients with available paired samples from both primary tumors and metastases were included in this study and re-analyzed by an independent and blind pathologist. HER-2 status was evaluated by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH); ER and PR status were assessed by IHC. Results: The median age was 40.3 years (range: 27.6∼87.4 years) and 25(83%) patients were premenoposal status. For paired metastases, a change in ER status was observed in 3 cases (10%): 2 cases from positive to negative, while 1 case converted from negative to positive and a change in PR status was observed in 4 cases (13.3%). HER-2 status was not changed in all cases based on IHC and FISH technique. In addition, there was a strong correlation of amplification index (AI) between primary and metastatic tissue based on FISH test (p & lt;0.0001). Conclusions: This study suggests that while there was around 10% of discordance rate for hormone receptor status, HER2 receptor discordance was not found between primary and metastatic breast cancer samples. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3292.
Materialart:
Online-Ressource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.AM10-3292
Sprache:
Englisch
Verlag:
American Association for Cancer Research (AACR)
Publikationsdatum:
2010
ZDB Id:
2036785-5
ZDB Id:
1432-1
ZDB Id:
410466-3
